Phase 3
Completed N=92
A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -
Source: ClinicalTrials.gov NCT00566020 ↗Enrolled (actual)
92
Serious AEs
14.1%
Results posted
Jul 2011
Primary outcomePrimary: Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event — 13; 75 participants
Summary
This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779 (NCT00550407)), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event |
13; 75 | — |
| PRIMARY Number of Participants With the Indicated Clinical Laboratory Test Values for Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) |
1; 89; 2; 2; 82; 0 | — |
| PRIMARY Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Bilirubin and Creatinine at Weeks 0, 6, 16, 28, 40, and 52/EW |
5; 87; 0; 5; 79; 0 | — |
| PRIMARY Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Calcium, Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at Weeks 0, 6, 16, 28, 40, and 52/EW |
1; 91; 0; 4; 80; 0 | — |
| PRIMARY Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Platelet Count and White Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW |
3; 89; 0; 2; 81; 1 | — |
| PRIMARY Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Protein, Hemoglobin, and Hematocrit at Weeks 0, 6, 16, 28, 40, and 52/EW |
1; 85; 6; 0; 77; 7 | — |
| PRIMARY Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Red Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW |
2; 88; 2; 1; 78; 5 | — |
| PRIMARY Number of Participants in the Indicated Category for Urine Glucose, Urine Protein, and Urine Urobilinogen at Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW |
88; 1; 1; 1; 0; 1 | — |
| PRIMARY Mean Systolic Blood Pressure and Diastolic Blood Pressure of Participants at Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW |
119.9; 121.7; 118.9; 119.0; 120.4; 118.6 | — |
| PRIMARY Mean Heart Rate of Participants at Week 0 (Baseline) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW |
76.3; 78.0; 77.4; 78.5; 77.0; 76.8 | — |
| PRIMARY Mean Weight of Participants at Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW |
60.86; 61.62; 61.29; 61.26; 61.38; 61.19 | — |
| PRIMARY Mean Body Mass Index (BMI) of All Participants at Week 0 (Baseline) and Weeks 6, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48, and 52/EW |
22.8; 23.01; 22.89; 22.93; 22.96; 22.86 | — |
| PRIMARY Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 0, 6, 28, and 52/EW |
73; 19; 0; 0; 69; 15 | — |
| SECONDARY Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW |
2.9; 2.9; 2.6; 2.5; 2.5; 2.3 | — |
| SECONDARY Change From Baseline in the Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW |
-0.3; -0.3; -0.4; -0.5; -0.5; -0.6 | — |
| SECONDARY Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW |
5.2; 4.3; 6.1; 5.2; 5.5; 4.5 | — |
| SECONDARY Change From Baseline in the Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW |
-4.5; -4.7; -3.7; -3.8; -4.3; -4.5 | — |
| SECONDARY Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW |
3.2; 2.6; 2.6; 1.7; 2.8; 2.0 | — |
| SECONDARY Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW |
0.2; -0.3; -0.4; -1.3; -0.2; -1.1 | — |
| SECONDARY Median Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection) |
1605.70 | — |
| SECONDARY Median Serum Lamotrigine 100 mg and 200 mg Concentration Among Participants With Concomitant Use of Inhibitor (at the Timing of Blood Sample Collection) |
5312.30; 6935.40 | — |
| SECONDARY Median Serum Lamotrigine 25, 100, 125, 150, 200, 225, 300, and 400 mg Concentrations Among Participants Without Concomitant Use of Inhibitor and Inducer |
699.95; 2793.55; 3505.30; 5418.40; 4092.30; 3594.25 | — |
Eligibility Criteria
Inclusion Criteria
- Of subjects participating in the preceding double-blind study, those who are judged by the investigator/sub-investigator to have well tolerated the double-blind treatment and to be eligible for the 52-week extension treatment
- Sex: either sex. Female of child-bearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the start of this study, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of contraception from the start of this study until the end of the follow-up examination:
Abstinence
Oral contraceptive, either combined or progestogen alone (except during the Dosage Adjustment Phase)
Injectable progestogen
Implants of levonorgestrel
Estrogenic vaginal ring (except during the Dosage Adjustment Phase)
Percutaneous contraceptive patches (except during the Dosage Adjustment Phase)
Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam / gel / film / cream / suppository)
- In/Out patient: Either
- Informed consent: the subject capable of giving written informed consent
Exclusion Criteria
- Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator
- Has a history of severe rash or rash due to anti-epileptic drugs
- Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic disorder. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (PAB/SD Notification No. 80, dated 29 June 1992)
- Patients have less than 5 years of remission history from clinically significant malignancy (other than e.g. basal cell or squamous cell skin cancer, in-situ carcinoma of cervix or prostate CA in situ)
- Patients with chronic hepatitis typeB and /or typeC which is positive of hepatitis B surface antigen （HBsAg）and/or hepatitis C antibody
- Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or has any unstable physical symptoms likely to require hospitalisation during participation in the study
- Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study
- Has a history or current diagnosis of epilepsy
- Has received an investigational drug within 30 days of screening
- Patients with a history of drug allergy to any ingredient of the test-drug
- Patients whom the investigator or sub-investigator considers ineligible for the study
Data sourced from ClinicalTrials.gov (NCT00566020). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.